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Technical issues with ex vivo CTC culture 241of tumor cell heterogeneity, it is important to amplify all the CTCs in a blood sample for a
comprehensive understanding of their role in cancer metastasis. By analyzing critical steps
and technical issues in ex vivo CTC culture, we developed a cost-effective and reproducible
protocol directly culturing whole peripheral blood mononuclear cells, relying on an assumed
survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified
cluster of cancer cells.
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Given its life-threatening consequences, cancer metastasis
could be considered the most crucial topic in cancer
research. The mechanism of metastasis should be intensely
investigated to define the critical players for therapeutic
targeting to improve patient survival. Based on historical
precedents, in which once-incurable diseases became
curable or successfully managed by medical oncologists
after advances in biomedical and clinical science [1,2],
cancer metastasis will be curable in the future. The overall
cancer death rate in the United State, for example, has
been falling over the last few decades [3], thanks mainly to
the identification of tobacco use as an oncogenic risk factor
and a protracted period involving in multistep nature of
carcinogenesis. In addition, the recognition of extensive
tumor cell heterogeneity has led to personalized oncology,
which is markedly improving cancer treatment and patient
survival [4e6]. A full understanding of metastatic tumor
pathophysiology, in combination with a careful examination
of the tumor microenvironment for a clear definition of
participant cell types and the signaling network in cancer-
stromal and cancer-host immune interaction, may provide
clinicians with critical mechanistic insights into the treat-
ment of cancer metastasis [7,8].
This review discusses one of our ongoing research pro-
jects focusing on isolation and characterization of circu-
lating tumor cells (CTCs) following ex vivo culture.
Expanding CTCs in large quantities will facilitate detailed
genotypical and phenotypical examination, allowing
causal abnormalities driving cancer metastasis to be
accurately identified and exploited as biomarkers for
cancer diagnosis, prognosis and treatment. Thus, estab-
lishment of a highly reproducible and efficient CTC prop-
agation protocol holds the promise for advancing precision
medicine and personalized oncology. This review summa-
rizes the current status of high quality CTC research re-
sults with special emphasis on ex vivo culture of this
specific cancer cell type. Based on published literature
and our own work, we comment on critical issues facing
the development of CTC culture methodologies and pro-
pose a rational strategy for culturing CTCs from cancer
patient peripheral blood samples. The goal of this dis-
cussion is to attract research interest to the development
of a cost-effective and reproducible protocol for ex vivo
culture of a limited number of CTCs from a given clinical
blood sample into a large population amendable to mo-
lecular characterization.2. Limitations in the research of cancer
metastasis
Many confounding factors make the study of cancer
metastasis more difficult than the study of oncogenic
initiation, promotion and progression. Firstly, the study of
cancer initiation is based on a unified hypothesis, which
postulates that cancer initiation is due to genomic mutation
or genetic abnormality, while environmental risk factors
promote these perturbations and culminate in cancer
development and local invasion. In contrast, metastasis is
shown to be the result of interplay between cancer cells
and resident cells of the tumor microenvironment,
involving mesenchymal, endothelial and immune cells at
secondary organ sites [9e11], where many of these
bystander cell types potentially affect cancer cells through
multiple reciprocity [12,13]. The presence of plural vari-
ants both in heterogeneous cancer cells and host micro-
environment makes identification of critical effectors
difficult. Secondly, the study of cancer development has a
longer history facilitated by having immortalized cell lines
as study subjects and genetically reconstituted animal
models to investigate how specific genetic mutations affect
cancer development. The study of cancer metastasis is less
granular, due to the difficulty of manipulating the drivers of
cancer metastasis, while animal models often fail to reca-
pitulate human metastatic profiles. Thirdly, cancer initia-
tion and development can be studied with defined
experimental systems, in which the effect of a suspected
causal factor can be quantitatively evaluated by multiple
modalities such as cell proliferation, apoptosis, migration,
invasion and xenograft tumor formation. The study of
cancer metastasis, by contrast, is often hindered by a lack
of optimal model systems to decipher the interaction be-
tween cancer cells and the tumor microenvironment at the
metastatic site. Finally, from the therapeutic perspective,
many primary cancers can be cured either by surgery and/
or adjuvant therapy, while there is a general lack of con-
fidence in the curability of cancer metastasis [14e16],
which often leads to the patient’s demise. It is challenging
for investigators to establish reliable in vitro models to
delineate the mechanism of cancer metastasis at an
organismic level. It would be ideal if metastatic cancer cell
lines could be established routinely from each individual
cancer patient.
Human cancers are broadly categorized into two groups
according to their lineage origin, tumors from mesenchymal
lineage and cancers of epithelial cell origin. Though the
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histopathologic analysis has shown that these two groups of
malignancies have distinctive natures of development,
progression and metastasis [17,18]. In the following dis-
cussion, the term “cancer” refers mainly to malignancies of
epithelial origin.
Many cancer theories assume that compared to normal
cells, tumor cells acquire survival and proliferation advan-
tages through tumor cell evolution in situ. Counterintui-
tively, tumor cells of epithelial origin are difficult to
amplify by ex vivo culture [19e21]. Only a few successes
have been achieved establishing immortalized cancer cell
lines. Pancreatic cancer, for example, is a fast progressing,
highly metastatic and devastating disease, but only a few
invasive human pancreatic cancer cell lines have been
established to date [22,23]. The same is true of prostate
cancer, another highly lethal disease with high incidence in
Western countries [24]. Cell line scarcity makes it espe-
cially difficult to study cancer cell heterogeneity, known to
contribute ultimately to cancer progression and to anti-
tumor therapeutic resistance. More importantly, the
inability to culture cancer cells from patient tumor tissues
makes it difficult to practice precision oncology at the
personalized level. It would be ideal to grow tumor cells
ex vivo from every cancer patient, and to then subject
these cells to screening for the most effective regimen
specifically tailored to the individual patient. An improve-
ment in primary human cell culture would contribute to the
advancement of cancer research and precision-based can-
cer treatment.
Our laboratory’s research focus on the mechanism of
cancer metastasis has revealed the importance of cellular
interactions, which collectively contributing to metastatic
dissemination of prostate cancer cells to the mouse skel-
eton [7,8,25e29]. We have found that cancer cells can re-
cruit and reprogram naı¨ve non-tumorigenic bystander cells
to participate in tumorigenic and metastatic cascade via
activation of critical transcription factors that confer
mesenchymal, stemness and neuroendocrine phenotypes to
the bystander cells [25,30,31]. These results exposed a
previously unrecognized facet of cancer metastasis: though
the mechanism of cancer initiation and development in
primary tumors may be a tumor cell-centered event, cancer
metastasis is a bona fide systemic disease, in which many
innocent cell types in the tumor microenvironment can be
“transdifferentiated” to express malignant phenotypes and
become active participants in the process of tumor cell
spreading. Detection of these newly converted cells may
provide sensitive biomarkers for metastasis detection, and
blockade of the recruitment and reprogramming mecha-
nism could be a new approach to delay metastasis and
prolong patient survival.3. CTCs as a marker of cancer metastasis
There is a general lack of sensitive biomarkers for diag-
nosis, treatment, and prognosis of many metastatic cancers
[32]. Conventional cancer research relies on comparative
analysis of cancer versus normal control cells to identify
differential biomarkers. Extensive biomarker search has
yielded few bona fide cancer biomarkers, partly becausethe survival advantage of cancer cells is achieved by
coopting normal regulatory mechanisms, rather than by
activating cancer-specific “oncogenes”. Shared structure
and gene expression between cancer and normal cells
would make it almost impossible to use “cancer-specific”
biomarkers to distinguish the presence of cancer from other
nonmalignant cells. In addition, published data in the
literature suggest that abnormalities of cancer cells are
dynamic, changing from one pathologic state to another
along with abnormal cell division [6,33,34]. Clinically, only
the appearance of certain morphologically distinct cells,
indicative of cancer, in the secondary organ sites is taken as
a concrete sign of cancer metastasis.
Many forms of patient samples can be used for disease
diagnosis, but the most common and least invasive sampling
is liquid biopsy of peripheral blood. In cancer research, it
has long been postulated that the circulation system is a
thoroughfare for cancer spreading [35e37]. This postula-
tion has now been supported by accumulating evidence, as
cancer cells have been detected and isolated from blood
samples both experimentally [38e40] and from clinical
cancer patients [41e43]. CTCs in cancer patient blood form
an attractive liquid biopsy compartment that can be sub-
jected to molecular interrogation to unveil genomic ab-
normality in tumor cells and their fate in the metastatic
cascade. With in-depth characterization, CTCs per se or
unique features of the CTCs may be used clinically for the
diagnosis, prognosis and treatment of cancer metastasis in
the future [44].
4. Argument for the necessity of ex vivo CTC
culture
There are two strategies for studying CTCs. The popular
strategy presently is to study CTCs directly from patient
blood. In a few cases, CTCs are amplified ex vivo into a
large population before investigation. We believe that for
reproducible investigation, especially for behavioral char-
acterization, CTCs have to be amplified, preferably into
stable cell lines.
4.1. The practical value of ex vivo CTC culture
A manifest disadvantage of directly detecting CTCs for
cancer diagnosis is the sparse and sporadic nature of this
abnormal cell type, which is mixed among the vast pop-
ulations of peripheral blood mononuclear cells (PBMCs)
[42,45,46]. This feature makes it difficult to perform any
comprehensive and reproducible analyses directly, either
for CTC detection and enumeration at the cellular level,
or for genomic and gene expression studies at the mo-
lecular level. Indeed, partly due to CTC heterogeneity
and partly due to present-day technological limitations,
even a confident counting of CTCs in any given patient
blood sample is hard, as is correlation of CTC counts to
disease progression or metastasis. Contributing factors
to the conundrum and the anemic understanding of
CTCs as a pathologic and tumor progression entity will
be discussed in detail in the following sections. It
seems that for CTC biomarker identification, an assess-
ment of the heterogeneity of genomic and gene
Technical issues with ex vivo CTC culture 243expression abnormalities can be made only by acquiring a
large amount of CTCs for concise molecular analyses and
reproducible validation [47].
4.2. Unknown fundamental biophysical and
biochemical information of the CTCs
Our marginal knowledge of CTCs is in stark contrast to our
profound understanding of the normal constituents of the
peripheral blood. Whereas each blood cell type has been
meticulously studied for its biophysical, biochemical, gene
expressional and behavioral characteristics, none of these
aspects is clearly defined for CTCs in the same sample.
Individual PBMC constituents, for instance, are well char-
acterized for their total counts, differential ratios, lineage
relationships, distinct cell sizes at resting state, cellular
densities, cytoplasmic granularities, nucleus morphologies,
surface markers, growth and differentiation capacities,
half-lives in circulation, biological functions and possible
pathophysiologic abnormalities. All these features could be
explored for the enumeration and isolation of a specific
PBMC fraction. In contrast, none of these features has been
fully explored in CTCs, making it difficult to conduct unbi-
ased detection and isolation of this abnormal cell type from
the vast blood cell population. Ultimately the unique fea-
tures of CTCs can only be identified by detailed charac-
terization of live CTCs.
The objective of ex vivo CTC culture is to expand the
limited numbers of CTCs in a given blood sample into a
large population, preferably into an immortal cell line, so
that molecular, cellular and behavioral investigations can
be conducted on these cells with high accuracy and
reproducibility.
5. Low success rate as the default of ex vivo
CTC culture
Many attempts have made to propagate CTCs through
ex vivo culture, with only limited success. This can be
demonstrated by the fact that though a huge literature on
CTC research is available, only about 50 publications in the
last decade address culturing CTCs from clinical patient
blood samples. Most of these cultures are short-term,
lasting from 3 days to 14 days [48e61]. Only a few long-
term cultures have reported successfully established CTC
lines with demonstrated immortality that could be cultured
stably for many passages [62e65]. These successes are
summarized in Table 1.
Though ex vivo CTC culture currently has low success
rates, the successes indicate that some CTCs in patient
blood are immortal and could be cultured ex vivo into
stable cell lines. In this discussion, long-term CTC culture
will be the main issue of examination, mainly because long-
term CTC culture is hindered by technical difficulties [19].
5.1. Rarity of CTCs by detection and enumeration
The main difficulty is the extreme rarity of CTCs. For
instance, a peripheral blood sample contains huge numbers
of red blood cells (around 5  109/mL), platelets (around4  108/mL), and PBMCs (around 6  106/mL). In contrast,
CTC counts in published studies have been detected as two-
digit numbers in a 7.5 mL blood [66]. CTCs thus exist as a
minute fraction among the vast number of blood cells, and
without ex vivo expansion it would be difficult to conduct
any comprehensive characterization on this elusive cell
type.
5.2. The caveat of using peripheral blood for
translational CTC study
CTCs are presumed to be in a dynamic equilibrium with
homeostasis of the tumor in situ, and are considered as a
surrogate marker for tumor status. CTCs, however, may not
be uniformly distributed in the blood. Analogous to the non-
uniform distribution of cells, proteins, hormones, and gases
in the circulation system, a non-uniform CTC distribution
should be expected, based on anatomy and physiology of
the circulation system. As depicted in Fig. 1, distribution of
CTCs may be determined by two factors: origin of the CTCs,
and size of the CTCs. Individual CTCs will be filtered
through two serial capillary beds; and in periphery, CTCs
are transported in parallel circuits. Structure of the sys-
temic circulation implies that peripheral blood may only
contain the least and smallest CTCs. Nonetheless, it is this
fraction of rare and small CTCs that are mediating tumor
spreading. The clinical value of peripheral blood sampling
for CTC detection and enumeration should be critically
evaluated.
5.3. CTC immortality
Though immortality is ideal for ex vivo CTC culture, in the
clinical setting immortality is not essential for CTCs to
metastasize from the primary tumor to a distant site. A CTC
does not have to be immortalized to cause metastatic
growth, as long as a viable CTC can be transported to
distant sites by the circulation system, which is known to be
swift and highly efficient for corporal distribution. This
presumption is in agreement with the finding that CTCs
from patient blood are vulnerable [67,68], just as they are
susceptible to ex vivo culture conditions [19]. Based on
extremely low published success rates, and our own CTC
culture experience, it is intriguing to postulate that until
late cancer stages, when heterogeneity becomes so thor-
ough that certain tumor cells have extensively evolved,
immortal CTCs may be rare in the patient’s blood. This
observation predicts that, by default, ex vivo culture
should be a low-success-rate practice, especially when a
large number of cancer patients are sampled without pre-
selection for late-stage cases. Development of an optimal
protocol for ex vivo culture is thus a critical subject for
reproducible CTC research.
6. Technical issues in the various CTC isolation
methods
It is habitual to assume that, in order to culture CTCs, these
cells should first be isolated from patient blood samples.
Most reported CTC culture protocols employ a two-step
Table 1 Summary of successes in long-term CTC culture with clinical cancer patient blood samples.
Disease Method of CTC
isolation
CTC culture conditions Group
size
CTC lines
established
Morphology Reference
Breast
cancer
CD45/CD66 iChip
negative selection
RPMI 1640 medium,
serum-free, with EGF, FGF,
and B27, in 4% O2,
spheroid culture
36 6 Spheroids Yu, et al.,
2014 [62]
Colon
cancer
CD45 RosetteSep
negative selection
DMEM: F12 medium, 2% FBS,
with insulin, EGF, and bFGF,
supplemented with N2,
in 2% O2 for 2 weeks;
then in RPMI 1640 medium,
2% FBS, with insulin, EGF,
bFGF, supplemented with
transferrin and selenite,
in normoxia
71 1 Spheroids Cayrefourcq,
et al., 2015 [63]
Prostate
cancer
Ficoll-Paque density
gradient and CD45
RosetteSep negative
selection
DMEM: F12 medium, with EGF,
bFGF, FGF10, supplemented
with R-spondin 1, DHT, B27,
nicotinamide, A83-01,
SB202190 and Y27632,
in Matrigel
17 1 Spheroids Gao, et al.,
2014 [64]
Small cell
lung cancer
Ficoll-Hypaque
density gradient
RPMI 1640 medium, serum-free,
with insulin, IGF-1 and selenite
30 3 Spheroids or
attached
Hamilton,
et al., 2015 [65]
bFGF, basic fibroblast growth factor; CTC, circulating tumor cells; DHT, dihydrotestosterone; EGF, epidermal growth factor; FBS, fetal
bovine serum; FGF, fibroblast growth factor; IGF-1, insulin-like growth factor 1.
244 R. Wang et al.strategy: isolating the CTCs from whole blood and then
subjecting the isolated cells to ex vivo culture under
defined conditions. A summary of CTC isolation strategies is
shown in Fig. 2. Though there are many conventional
technologies for isolating a specific cell type from a mixed
sample, none is suitable for the isolation of CTCs from
cancer patient blood, because specific traits that can be
explored for a clean isolation of CTCs have not yet been
defined.
6.1. CTC isolation by density gradient fractionation
In many reports, CTCs are initially isolated from erythro-
cytes together with the PBMC population. Cellular density-
based isolation with Ficoll polysaccharides is one of the
best-established methods for isolating PBMCs from a blood
sample. This method, nonetheless, only allows the isolation
of a lighter fraction of the PBMCs. Ficoll-Paque medium
with a density of 1.077 g/mL (Ficoll-Paque 1077), for
example, selectively isolates monocytes and lymphocytes
that in comparison to red blood cells, have lighter den-
sities [69,70]. The use of Ficoll-Paque with a density of
1.084 g/mL may additionally isolate basophils, but leaves
behind heavier neutrophils and eosinophils. In our study of
CTCs from prostate and pancreatic cancer patient blood
samples [42], some candidate CTCs appeared much heav-
ier, and could not be isolated by Ficoll-Paque 1.077 or 1.084
banding. Because the density of CTCs is not defined and
probably is not uniform, using density gradient to isolate
CTCs in monocyte/lymphocyte banding is not supported by
biophysical data.Alternative strategies for isolating CTCs directly from
blood sample encounter difficulties as well. Most such
methods are based on surface marker expression: detecting
and isolating CTCs that bear a predetermined surface
marker absent from normal blood cells. Both positive and
negative selection strategies are commonly used. Neither
of these strategies guarantees a comprehensive isolation of
all the CTCs in a given sample, but may introduce compli-
cations to later analyses.
6.2. CTC isolation by positive selection
To isolate by positive selection, CTCs are presumed to have
retained surface marker expression of the primary tumor
cells. Since primary cancers are of epithelial origin, and
since most cancer cells carry epithelial surface markers,
these markers are often applied for fishing CTCs from the
blood. Epithelial marker expression, however, is known to
be altered and may even be lost in cancers. The epithelial
cell adhesion molecule (EpCAM), for example, is universally
expressed on normal epithelial cells. It is involved in
maintenance of intercellular adhesion in an epithelial
layer, clenching epithelial cells into a static and docile
state [71,72]. During cancer development and progression,
however, its expression would be reduced or lost [73e75]
due to multiple oncogenic signaling, or through epithelial
to mesenchymal transition. Significantly, loss of these types
of epithelial markers accounts for the acquired mobility,
and invasive and migratory potential, of cancer cells. The
formation and shedding of CTCs into blood circulation,
therefore, could imply that these special cancer cell types
Figure 1 Size-limiting structure of the blood circulation
system. A diagram of the human blood circulation system
shows the likeliest site to find CTCs. Pulmonary circulation
(upper portion) may be considered as a serial perfusion system,
transporting CTCs (golden balls) from lung tumors to the
oxygenated blood (red), where the CTCs will be filtered by
peripheral capillary beds. Systemic circulation (lower portion)
is comprised of parallel vascular systems. Two parallel capillary
beds are used to show scenarios of CTC circulation. In one
scenario, CTCs (red balls) from tumors of visceral organs may
be shed to the internal vein, and will be filtered by the pul-
monary capillary network. In another scenario, blood samples
from upper limb superficial veins are commonly used for CTC
studies. Though this is convenient and less invasive for routine
clinical phlebotomy, cancer patient blood samples from these
veins may contain only the smallest CTCs in size and the fewest
CTCs in number. According to this diagram, CTCs from lung
tumors may be easier to detect in arterial blood, whereas CTCs
from tumors in other organs may be easier to be detected from
the blood approximate to the right side of the heart.
Technical issues with ex vivo CTC culture 245have lost most of their EpCAM surface expression. Due to
tumor cell heterogeneity in epithelial marker expression,
the use of epithelial proteins as surrogate cancer cell
markers may detect certain CTCs, but may not be an ideal
strategy for comprehensive isolation of all the CTCs in a
given blood sample. Importantly, it should be kept in mind
that the CTCs whose epithelial behavior is completely lost
might be the ones that are more representative of the
malignant stage of disease [76e78].
Another drawback to positive selection is that this
method is inherently harmful to CTCs, as isolated CTCs areno longer viable for ex vivo culture. Firstly, antibody-
binding could be harmful to cell survival. Some antibodies
against EpCAM, for example, may directly cause cancer cell
death [79] or indirectly induce antibody-dependent cell-
mediated cytotoxicity (ADCC). Indeed, anti-EpCAM medi-
ated cancer cell killing is a mechanism sought in studies
involving adecatumumab, edrecolomab and catumaxomab.
Secondly, positive selection relies on mechanisms such as
antibody-antigen ligation, ligand-receptor binding, or
integrin-extracellular matrix (ECM) adhesion for CTC
recognition. To physically isolate CTCs, the recognition part
of the ligands in the forms of antibodies, peptides, or
organic molecules, has to be affixed onto a solid or semi-
solid surface, either magnetic beads, microfluidic chips,
or polysaccharides, so the CTCs can be tethered onto the
surface and then isolated by physical means. In many cases,
isolated CTCs remain affixed onto the solid surface and are
easily killed by dehydration. In some cases, live CTCs may
actively attach onto the surface due to close adjacency. To
free the isolated CTCs from the solid surface, either
enzymatic digestion to break the affixation or laser capture
micro-dissection (LCM) would most likely kill the CTC as
well.6.3. CTC isolation by negative selection
Technical difficulties are similarly seen in CTC isolation by
negative selection, which is designed to deplete all normal
PBMCs from a blood sample using well-known hematopoi-
etic surface markers, leaving only CTCs behind. The major
drawback with this strategy is that not all normal cells in a
blood sample can be removed by negative selection,
because a fraction of hematopoietic cells does not express
known hematopoietic surface markers [80]. In addition, not
all blood cells are hematopoietic, so a peripheral blood
sample may contain many non-hematopoietic cell types
besides CTCs [81].
CD45 isoforms, for example, are said to be expressed on
all cells of the hematopoietic lineage and are commonly
used in negative selection to deplete hematopoietic cells
from blood. Not all blood cells, not even all hematopoietic
cells, are CD45-positive [80]. Though the frequency of
CD45-negative cells in human blood has not been system-
atically quantitated, this fraction of cells is attracting more
research. In different patient groups and with different
detection settings, CD45-negative cells are found to range
from 0.02% [82] to almost 2% [80] of PBMCs. These may
translate into a CD45-negative count ranging from 1200/mL
to 120,000/mL blood sample, still much higher than the
assumed two-digit CTC counts in the same volume. The
result of a CD45-negative selection, therefore, is CTCs
mixed with many poorly characterized but otherwise
normal cells of the blood. Similarly, an alternative negative
depletion with human lineage marker (Lin, a cocktail of
antibodies against known cell types of the entire hemato-
poietic lineage) would result in CTCs mixed with various
Lin-negative normal cells [80,83]. Though negative
selection may have less effect on CTC viability, this
method fails to yield a pure CTC population and will
potentially be misleading by totaling enriched normal blood
cells as CTCs.
Figure 2 Current methodologies for ex vivo CTC expansion. Current strategies, methods, and technologies employed in CTC
culture are summarized in this flowchart. Arrowed lines denote blood sample manipulative steps. Thin blue lines in the flowchart
indicate the unique experimental steps developed in our laboratory. CDX, CTC-derived xenograft; CTC, circulating tumor cells;
LCM, laser capture micro-dissection; 2-D, two-dimension; 3-D, three-dimension.
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In addition to negative selection, there are other isolation
methods that may not guarantee a successful CTC isolation
and may instead introduce distortions in CTC quality and
quantity. Size-based isolation, for example, may not be
able to isolate all the CTCs from a given blood sample,
simply because the size distribution of CTCs in a given blood
sample is unknown. It is possible that, similar to established
cancer cell lines, CTCs in a given patient blood sample may
have varied cell sizes, overlapping the size range of resi-
dent hematopoietic cells. This complexity is compounded
by the fact that PBMCs in the same blood sample highly vary
in size as well, with diameters ranging from 7 mm for resting
lymphocytes up to 30 mm for monocytes.
On the other hand, lumen dimensions of the limiting
capillary micro-vessels range from 7.5 mm to 10 mm in
diameter, and pulmonary capillaries could be even nar-
rower [84]. To be free to travel throughout the circulating
system, a CTC may have to adopt a small size, or not be
markedly larger than PBMCs; otherwise CTCs may not
circulate through capillary vessels. The relationship of size-
limiting capillary beds and CTC distribution is shown in
Fig. 1.As shown in Fig. 1, a size-limiting structure of the blood
circulation system additionally indicates that, unless blood
has to be sampled from large internal veins of the patient,
it would be difficult to expect that a size-based method
could isolate out any pure CTC population. In this regard, a
more invasive sampling from large visceral organ-draining
veins could indeed catch large cancer cells and even large
tumor cell clusters [85e87], while our group has identified a
type of CTCs with a small nucleus from peripheral blood
samples, which correlated with the state of castration-
resistant progression and metastasis of prostate cancer
[45].
The distribution of CTCs in blood circulation is not uni-
form, but is limited to certain segments of the vasculature.
As pointed out in Fig. 1, any CTCs will be filtered against
two in-serial capillary beds, which must have enormous
anti-tumor capacities for purging all the trapped CTCs.
Also, the anatomical site of blood draw has to be consid-
ered in CTC research. Arterial blood may be CTC-rich for
cancers of the pulmonary circulation, and vena cava blood
should be rich for CTCs from other organs perfused by
systemic circulation. In any case, because of capillary
filtration and the parallel pattern of systemic circulation,
peripheral blood always represents a CTC-poor sample
Technical issues with ex vivo CTC culture 247(Fig. 1), although peripheral phlebotomy is the most
convenient and least invasive sampling route.
As discussed above, the term “CTC” is presently an
operational concept, simply denoting any cancer cells
being shed from a tumor into blood circulation. Cancer cells
are highly plastic and are in dynamic evolution with pro-
cesses mimetic to stem cell differentiation [88], trans-
differentiation [89], or somatic cell fusion [26]. Cancer cell
evolution ultimately results in a highly heterogeneous cell
population, with individual cells in a given patient dis-
playing a wide spectrum of biophysical, biochemical, gene
expressional and behavioral alterations, none of which will
be representative of the entire tumor cell population.
Similar scenarios of cellular heterogeneity may be present
in the CTCs in a patient’s blood sample, and any CTC
studies based on a predetermined parameter would only
detect and isolate a fraction of the whole CTC population.
7. Current status of ex vivo CTC culture
Presently, isolated CTCs are difficult to maintain in a viable
state, and are rarely cultured ex vivo into a large popula-
tion, least of all into stable CTC cell lines. Furthermore,
CTCs have been said to be an inherently vulnerable cell
type, possibly because the circulating blood may not be an
amiable environment for CTC survival [67,68]. All these
confounding factors make the isolation of viable CTCs
difficult.
7.1. Studying CTCs without amplification
Because isolated CTCs are not viable and cannot be
expanded in numbers by ex vivo culture, most ensuing
molecular and genetic investigations on CTCs have to be
performed on very limited numbers of CTCs, which yield
too few and too little starting materials for extensive and
comprehensive examinations. Presently, only a few
analytical methods may be adopted for CTC examination,
most as nucleotide-based assays, while the starting mate-
rial has to be pre-amplified with polymerase chain reaction
(PCR). Popular CTC assay methods include microarray
expression profiling, single-cell sequencing, and quantita-
tive PCR (qPCR) detection.
While single-cell analysis is a cutting-edge advance-
ment, accumulating results suggest that many technolog-
ical shortcomings of single-cell analyses remain to be
overcome. A single cell, for instance, can now be used as
starting material for whole exon sequencing with the next-
generation sequencing platform, but the result is often
suboptimal. As a single run on the platform routinely put
out more than one million sequencing reads, the reads from
a single-cell analysis are found with frequent base ambi-
guities, while computational analysis can assign only a small
fraction of these reads to a small fraction of encoding genes
in the human genome.
The scenario becomes even more problematic for
comparative studies, because many assigned reads in one
single CTC are not detectable in another single CTC, due to
randomness and the sporadic nature of whole exon
sequencing with limited starting material [90,91]. For“profiling” expression in a single CTC, the potential power
of next-generation sequencing is severely limited in single-
cell sequencing. It would be ideal if limited numbers of
CTCs could be amplified into a larger population by ex vivo
culture, so comprehensive genomic and genetic analyses
could be performed with high reproducibility and accuracy,
and then compared confidently among different CTC cul-
tures from individual patients against the stages of disease
development and progression.
7.2. CTC culture by short-term cultivation
Several laboratories have subjected isolated CTCs from
patient blood samples to short term ex vivo culture.
Enriched CTCs from PBMCs in free form or on solid surfaces
were cultured ex vivo for 3e14 days. In these studies,
choice of culture medium was mostly based on each labo-
ratory’s experience, as with long-term culture studies
(Table 1).
Reports with short-term culture demonstrated success-
ful ex vivo expansion of isolated cells, as determined by
amplification of cell numbers and colony formation
[48e61]. In many cases, the expanded cells were shown to
be suitable subjects for immunohistological analysis,
karyotypic examination, and gene expressional profiling.
As discussed above, short-term CTC culture may be
compromised by impurity of the CTC isolation or by a
distortion of the mixed blood cells. As the limited numbers
of colonies grown in short-term culture may alleviate the
limitations seen in single-CTC analysis, results of CTC
characterization from these studies have to be further
validated by additional means, because of the limits on CTC
reproducibility. Nonetheless, these results provide sup-
porting evidence that CTCs in patient blood samples can be
cultured. With careful optimization, these culture condi-
tions may be applied to successful long-term culture.
7.3. Long-term culture to establish stable CTC lines
It is difficult in general to culture human cells in vitro, and
even harder to culture human cells into cell lines. It is
similarly difficult to culture CTCs from cancer patient blood
samples, even though cancer cells are believed to have
evolved survival and proliferation advantages. As summa-
rized in Table 1, there are nonetheless a few reports of
long-term culture success, in which CTCs in cancer patient
peripheral blood samples have been expanded ex vivo into
large population, and a few of these CTCs even showed the
capability of continuous passage for numbers of generations
[62e65], suggesting that similar to established cancer cell
lines, these CTCs may harbor immortality.
The capability for independent survival and growth is
said to be a watershed feature of cancer progression.
Tumor cells at advanced stages are thought to be able to
survive adversities in their surroundings and proliferate
indifferent to regulatory cues in the microenvironment.
Paradoxically, many ex vivo CTC cultures resort to the help
of cytokines, growth factors, tissue organ extracts, hor-
mones, and small molecules to facilitate CTC survival and
growth in vitro [62e65]. The optimal conditions for ex vivo
CTC culture remain to be defined.
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of stem cell culture conditions. Besides cocktails of con-
ventional cell culture mediums, proprietary mediums are
often used in CTC culture, but may not guarantee CTC
amplification. In addition to alternative choices of animal
serum, different recipes are found using epidermal growth
factor (EGF) and basic fibroblast growth factor (bFGF, or
FGF2), which are often seen in recipes for stem cell cul-
ture. Additional growth factors used include fibroblast
growth factor-10 (FGF10), granulocyte macrophage colony-
stimulating factor (GM-CSF), insulin and insulin-like growth
factor 1 (IGF-1). In some cases, R-spondin 1 protein is added
in an attempt to sustain survival and growth of epithelial
cells through WNT/b-catenin signaling [92]. In cases when
serum-free CTC culture media are used, the recipes mostly
include proprietary B27 and N2 supplements, together with
insulin, transferrin and selenium (ITS) supplementation.
Other factors that may promote stem cell growth are
also used, including dihydrotestosterone (DHT) and nico-
tinamide. In addition, small molecule inhibitors for specific
signaling pathways have been tested for promoting CTC
growth. Inhibitors of A83-01 and ALX-270-445, for example,
may specifically inhibit the function of TGFb type 1 re-
ceptor kinase (ALK5) and so prevent epithelial to mesen-
chymal transition and promote CTC survival and
proliferation. SB202190, a specific P38 inhibitor, may pre-
vent apoptosis due to P38 activation. Y27632, a cell
permeable inhibitor of Rho-associated coiled-coil contain-
ing protein kinase (ROCK), is used in CTC culture to promote
organoid growth and formation.
The most interesting phenomena in all the published CTC
culture studies is how few of the cultured CTCs display any
expectedmorphologies or behaviors of an epithelial lineage.
Instead, most of the successful cultures yielded CTCs
growing in suspension in 3-dimensions (3-D), aggregating to a
spheroid or organoid organization. Intriguingly, these
morphologic and behavioral features are commonly seen
with stem cell culture, and are taken as a sign of stemness
[93,94]. Though it remains to be determined whether CTCs
amplified by ex vivo culture are cancer stem cells, these
results confirmed that CTCs represent cancer cells that have
completely lost epithelial marker expression.
In addition to conventional suspension culture setups,
more ex vivo CTC cultures are adopting various 3-D formats.
Soft agar colony formation, non-adherent culture, and
spheroid or organoid culture on growth factor-reduced
Matrigel matrix are popular CTC culture systems. To
induce survival responses in CTCs, hypoxic culture condi-
tions or consecutive culture in hypoxic and normoxic envi-
ronment are used.
It should be noted that, because optimal CTC culture
condition has yet to be defined, current research relies on
stem cell culture methods to ensure a maximal CTC
expansion. Each protocol is designed based on the re-
searcher’s own expertise and empirical results, not by a
rationale based on CTC biological features, which are
presently not defined. Published protocols yielded very low
success rates, generally less than 5% of the patient blood
samples cultured. Rationale-based modifications should be
tested to improve the success rate.
One of the future modifications probably should be a
reduction or complete avoidance of exogenous growthfactors and small molecules in CTC culture, because CTCs
grown with the support of these factors may have limited
applications for the mechanistic investigation of cancer
progression and metastasis. Cancer cells already have ac-
quired growth and survival autonomy. On the other hand,
cancer metastasis, homing, and colonization are charac-
terized by cancer cell interaction with resident cells of the
mesenchymal lineage in the tumor microenvironment, and
the interaction has been shown to be mediated by growth
factors and can be modulated by small molecule signaling
pathway inhibitors. CTCs cultured in the presence of
growth factors and small molecule inhibitors thus may not
be ideal subjects for modeling cancer and stromal
interaction.
8. Our experience with ex vivo CTC culture
Our laboratories study the mechanism of cancer progression
and metastasis. As CTCs are plausible mediators in distant
tumor cell spreading, we used mouse xenograft models to
track CTCs during metastasis [39,95]. In recent years, we
have established close collaborations with clinical oncolo-
gists and surgeons in translational studies with clinical blood
samples from cancer patients. These intercalated research
interests led to a platform for translational research on
critical issues relevant to the welfare of cancer patients.
8.1. Modeling CTC culture with experimental
animals
We initially carried out studies in tumor-bearing mice to
confirm that there indeed were CTCs in animal blood. To
facilitate tracking live CTCs, we tagged the ARCaPE human
prostate cancer cells with a stable expression of red fluo-
rescence protein (RFP). Selected ARCaPE-RFP clones were
inoculated orthotopically to the prostates of athymic mice
for xenograft tumor formation, which caused a wide spread
of cancer cells to internal organs in addition to skeleton
[39,95]. In one of the experiments, intra-cardiac blood
samples were observed to contain red fluorescent cells,
indicating that metastasis of the xenograft tumor was
mediated by these cells.
We then drew blood from the tumor-bearing mice and
tested a basic protocol for expanding CTCs through ex vivo
culture [39]. This series of experiments led to the devel-
opment of a simple and cost-effective protocol, with which
CTCs in a drop of blood (about 75 mL) from either a tail cut
or from the left ventricle were enough to form multiple
colonies of red fluorescent cells. Interestingly, these col-
onies were markedly different from parental ARCaPE-RFP
cells in both morphological, behavioral and gene expres-
sional senses; and the changes were irreversible, with CTC-
derived clones losing most epithelial features and acquiring
conspicuous mesenchymal cell traits. We subsequently
repeated the ex vivo CTC culture with a different xenograft
model, in which RANKL overexpression converted androgen-
dependent non-tumorigenic LNCaP prostate cancer cells to
androgen-independent, highly tumorigenic, metastatic cells
[25]. From these mice, blood samples from retro-orbital
sinus, submandibular vein, tail cut and left ventricle could
all be cultured to form cancer cell colonies (unpublished
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ex vivo culture from clinical cancer patient blood samples.
8.2. Modification of PBMC isolation
We obtained cancer patient samples in the form of packed
blood cells, the cellular fraction after plasma was taken for
clinical use. In some cases, both blood and surgical tumor
from the same patient were sampled and subjected to
identical ex vivo culture, in order to validate the culture
method.
We first tested if CTCs were present in cancer patient
peripheral blood as well. PBMCs were isolated from pros-
tate cancer patient peripheral blood samples with two
methods. With the first method, density gradient banding in
Ficoll-Paque 1077 or 1084 was used to isolate the monocyte
and lymphocyte fraction. Candidate CTCs in this fraction
were detected with fluorescein-conjugated anti-EpCAM
antibody, together with NIR-783, a prototype heptamethine
carbocyanine near infrared organic dye, which we have
determined to have tumor cell specificity [96]. This exam-
ination demonstrated CTC-like signals in the patient blood,
and the count of these cells correlated well with disease
progression in general trends [42]. These results confirmed
that there were detectable numbers of CTCs in blood
samples of prostate cancer patients, especially in those
with advanced disease.
On the other hand, this series of experiments revealed
that density gradient centrifugation was not an ideal
method for isolating all CTCs from a given patient blood
sample, because after removal of the monocyte and
lymphocyte band, additional EpCAMþNIRþ signals could be
detected from the remaining heavier Ficoll-Paque frac-
tions. The signal was even detected from the heaviest
erythrocyte pellet. This finding indicated that in a given
cancer patient blood sample, heterogeneous CTCs might
vary in density, making gradient fractionation a less than
optimal method for comprehensive isolation of all CTCs
from the sample.
With the Ficoll-Paque isolated PBMCs, we additionally
tested whether CTCs could be sorted from PBMCs by flow
cytometry. Though anti-EpCAM antibody and NIR-783
stained cells could be isolated by flow cytometric sorting
in all the patient blood samples tested, the number of
sorted cells was mostly too low and too diluted in sorting
fluid for successful ex vivo culture.
The second method we tested was whole PBMC isolation
by ammonium chloride hemolysis. Because it recovers all
the nucleated cells from a blood sample in a cost-effective
and highly reproducible manner, ammonium chloride he-
molysis is now becoming the mainstay of PBMC isolation. To
assess whether it could be a favorable method for ex vivo
CTC culture, we found that some hemolysis formulas had
marked time-dependent toxicity to PBMCs and even to
established human prostate cancer cell lines. Accordingly,
we evaluated a series of formulas to identify a modified
recipe, which was potent for hemolysis but carried little
cytotoxicity to nucleated cells. In subsequent CTC cultures,
this modified PBMC isolation protocol has been found to be
markedly cost-effective, less labor intensive, and highly
reproducible.8.3. Culturing entire PBMC populations for ex vivo
CTC expansion
As discussed above, the process of isolation either affected
CTC viability or yielded a mixed cell population. In addi-
tion, CTC isolation is a costly practice not suitable to large
scale studies or routine CTC culture. We reasoned that the
isolation step may not be essential to ex vivo culture of
CTCs, if these specified cancer cells indeed had survival and
proliferation advantages over other constituent cells in
PBMCs. We explored the possibility of culturing CTCs by
skipping the isolation step.
It is well known that most blood cells of hematopoietic
lineage are terminally differentiated and have lost prolif-
eration capability. Though the T and B lymphocytes harbor
proliferation potential, proliferation has to be triggered by
specific antigen receptor ligation [97], by a Ca2þ influx
together with a PKC activation [98], or by super-antigen
cross-linking [99]. Moreover, the activated lymphocyte
proliferation is transient, ending with a programmed
activation-induced cell death [100e102]. In general,
without additional stimulation, PBMCs in resting state
would perish in ex vivo culture within days, each cell type
dying in a programmed manner. Macrophages are the only
cell type in PBMCs capable of survival for weeks in culture.
Macrophages, however, are also a terminally differentiated
cell type incapable of ex vivo proliferation. The constant
presence of some macrophages may not affect the survival
and proliferation of non-hematopoietic cells, including
CTCs. These observations suggested that CTCs could be
amplified naturally by culturing whole PBMCs, should CTCs
indeed have survival and proliferation advantages.
8.4. Choosing a culture medium
Different from culturing immortalized cell lines, which
would survive and proliferate in vitro under varied culture
conditions, culturing primary human cells is thought to
require specific culture conditions. For ex vivo CTC culture,
however, an optimal culture medium has yet to be defined,
because we do not know the preferred conditions for CTC
survival and proliferation, and because we are not even
sure whether the determinants for CTC survival and growth
reside within the cell or outside the cell.
To choose a practical medium formula for ex vivo CTC
culture, we tested various culture mediums and conditions,
with reference to published methods for various primary
human cells. We concluded that, though nutrition-rich or
stem cell culture mediums may prolong the survival of
primary tumor cells, some PBMCs, and probably CTCs, none
promoted cellular proliferation. Rather, the subject cells
adopted a “blast” morphology but undertook little cell di-
vision. In contrast, some regular recipes for routine main-
tenance of commonly used cancer cell lines were amiable
for the proliferation of CTC-like cells, which could survive
and grow into large population, some even showing
immortality behaviors, capable of proliferation beyond 60
continuous passages [103,104].
Our choice of conventional medium for CTC culture was
also supported by our results culturing surgical tumor
specimens from cancer patients. We have established new
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culturing clinical surgical tumor specimens (unpublished
data), and these cell lines are currently being character-
ized. As both nutrition-rich stem cell culture mediums and
conventional mediums facilitated outgrowth of tumor cells,
we found that immortalized cancer cell lines could only be
established from cultures in conventional medium, albeit at
low success rates. These observations strongly suggested
that, for primary human cell culture, survival and prolif-
eration is determined by mechanisms inside the cell, rather
than by the conditions of the ex vivo culture.
8.5. Establishing stable cultures of CTC-like cell
preparations
Using our ex vivo culture protocol, we have accumulated a
panel of immortalized cells from clinical cancer patient
blood samples. While these cells have yet to be fully
characterized, results from xenograft tumor formation
have confirmed their malignancy to be similar to the pa-
tients’ primary disease (unpublished data). With a cost-
effective and straightforward method established, further
fine tuning of culture conditions and standardizing phle-
botomy and sample preparation protocols may markedly
improve the success rates of CTC culture. Additionally, we
are identifying biomarkers from the established CTC-like
cell lines. Through CTC biomarker detection from pro-
spective patient blood samples, these CTC-like cell lines
will be validated as true CTCs. It is rational to predict that
in the future these markers will serve well as surrogates for
clinical CTC detection during cancer diagnosis, treatment
and prognosis, so time-consuming CTC culture from every
cancer patient would not always be needed for precision
oncology and personalized cancer therapy.
Though ex vivo CTC survival and proliferation are
determined by endogenous mechanisms, our preliminary
studies suggested that these abilities could be modulated
by exogenous growth factors and specific small molecule
pathway inhibitors, similar to published observations by
other laboratories. The application of exogenous factors,
however, could not increase the success rate of CTC culture
and might introduce undesired complications to further
investigation. For instance, upon intra-cardiac inoculation,
tissue-specificity of homing and colonization of the inocu-
lated CTCs in host mice would be determined by exogenous
cues in the tumor microenvironment [8]. We reasoned that
addition of growth factors in the ex vivo CTC expansion step
may pre-condition these cells into a peculiar state, and
thus complicate data interpretation in studies particularly
relevant to CTC colonization at secondary organ sites.
8.6. Establishment of CTC-derived xenograft tumor
models
Our ex vivo culture has resulted in the establishment of a
panel of CTC cultures from peripheral blood samples of
both pre-surgical and non-resectable pancreatic cancer
cases, and also from both primary pre-surgical and
castration-resistant and metastatic prostate cancer pa-
tients. Besides determining the malignant characteristics of
these CTCs in vitro, we assessed the tumorigenicity of eachof these preparations with a CTC-derived xenograft (CDX)
model. CTCs in mixture with Matrigel were inoculated
subcutaneously, intracardially or orthotopically to the
pancreas or the prostate of athymic mice. Prevalent and
rapid xenograft tumor formation and lethality were
observed in host mice, confirming the malignant nature of
these cells [103,104]. Importantly, the tumor-bearing mice
displayed frequent and multiple metastases in distant or-
gans. As it is well known that human cancer cell xenograft
tumors rarely cause metastasis in experimental mice, these
CDX models may have inherited the highly invasive and
metastatic nature of the patients’ in situ tumor. Charac-
terizations of the CDX models, in the context of correlation
with the original clinical specimens, and evaluation of their
application in prostate and pancreatic cancer translational
research are underway.
9. Conclusion
In this review, we critically examined the major steps of
ex vivo culture protocols, to identify the technical chal-
lenges to successful CTC amplification from cancer patient
blood samples. We think that the most critical issue facing
CTC research is the lack of information on the fundamental
characteristics of CTCs in terms of their biophysical,
biochemical, gene expressional, and behavioral features.
Due to this lack of information, no reliable methods can yet
be designed for isolating CTCs from vast numbers of blood
cells. A full illustration of the fundamental characteristics
of CTCs is an urgent topic in cancer research.
In keeping with overall cancer cell heterogeneity, CTCs
may be highly heterogeneous as well. Because it is chal-
lenging to isolate all the heterogeneous CTCs from a given
patient peripheral blood, in our laboratory we skipped the
CTC isolation step by culturing whole PBMCs in order to
amplify CTCs, relying on their survival and proliferation
advantages. Using this strategy, we have established a
panel of CTC-like cell lines from pancreatic, prostate,
kidney, breast and gastric cancer patient blood samples.
Full characterizations of these cells are underway. These
molecular interrogations could lead to the identification of
CTC biomarkers and molecular signaling network underlying
therapeutic responses and resistance observed in patients.
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